[go: up one dir, main page]

NO20030744L - Nye fenylalaninderivater - Google Patents

Nye fenylalaninderivater

Info

Publication number
NO20030744L
NO20030744L NO20030744A NO20030744A NO20030744L NO 20030744 L NO20030744 L NO 20030744L NO 20030744 A NO20030744 A NO 20030744A NO 20030744 A NO20030744 A NO 20030744A NO 20030744 L NO20030744 L NO 20030744L
Authority
NO
Norway
Prior art keywords
phenylalanine derivatives
new phenylalanine
integrin
chem
alpha
Prior art date
Application number
NO20030744A
Other languages
English (en)
Other versions
NO325738B1 (no
NO20030744D0 (no
Inventor
Shingo Makino
Tatsuya Okuzumi
Toshihiko Yoshimura
Yuko Satake
Nobuyasu Suzuki
Hiroyuki Izawa
Kazuyuki Sagi
Akira Chiba
Eiji Nakanishi
Masahiro Murata
Takashi Tsuji
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of NO20030744D0 publication Critical patent/NO20030744D0/no
Publication of NO20030744L publication Critical patent/NO20030744L/no
Publication of NO325738B1 publication Critical patent/NO325738B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20030744A 2000-08-18 2003-02-17 Nye fenylalaninderivater, alfa 4-integrinantagonister, samt farmasøytiske preparater og terapeutiske eller forebyggende midler omfattende disse NO325738B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000248728 2000-08-18
JP2001147451 2001-05-17
PCT/JP2001/007039 WO2002016329A1 (en) 2000-08-18 2001-08-15 Novel phenylalanine derivatives

Publications (3)

Publication Number Publication Date
NO20030744D0 NO20030744D0 (no) 2003-02-17
NO20030744L true NO20030744L (no) 2003-04-07
NO325738B1 NO325738B1 (no) 2008-07-14

Family

ID=26598103

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030744A NO325738B1 (no) 2000-08-18 2003-02-17 Nye fenylalaninderivater, alfa 4-integrinantagonister, samt farmasøytiske preparater og terapeutiske eller forebyggende midler omfattende disse

Country Status (27)

Country Link
US (4) US7153963B2 (no)
EP (1) EP1288205B1 (no)
JP (1) JP3440469B2 (no)
KR (1) KR100675036B1 (no)
CN (1) CN1325480C (no)
AT (1) ATE497385T1 (no)
AU (2) AU7874001A (no)
BG (1) BG66085B1 (no)
BR (1) BRPI0113331B8 (no)
CA (1) CA2420040C (no)
CZ (1) CZ302653B6 (no)
DE (1) DE60143984D1 (no)
DK (1) DK1288205T3 (no)
HU (1) HU228914B1 (no)
IL (2) IL154350A0 (no)
MX (1) MXPA03001495A (no)
NO (1) NO325738B1 (no)
NZ (1) NZ524122A (no)
PL (1) PL223152B1 (no)
PT (1) PT1288205E (no)
RU (1) RU2286340C2 (no)
SI (1) SI1288205T1 (no)
SK (1) SK287781B6 (no)
TW (1) TWI229077B (no)
UA (1) UA74385C2 (no)
WO (1) WO2002016329A1 (no)
YU (1) YU12203A (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337628B1 (no) * 2003-12-22 2016-05-18 Ajinomoto Kk Fenylalaninderivater eller farmasøytiske akseptable salter derav, en farmasøytisk sammensetning, en α4 integrin antagonist og et terapeutisk middel

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
NZ524122A (en) * 2000-08-18 2005-02-25 Ajinomoto Kk Phenylalanine derivatives useful as pharmaceutical agents
DE60124573T2 (de) 2000-09-29 2007-06-21 Ajinomoto Co., Inc. Neue phenylalanin-derivate
WO2003010135A1 (en) * 2001-07-26 2003-02-06 Ajinomoto Co., Inc. Novel phenylpropionic acid derivatives
WO2003053926A1 (en) * 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Novel phenylalanine derivative
EP1477482B1 (en) 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Novel phenylalanine derivative
ES2548419T3 (es) 2003-02-20 2015-10-16 Ajinomoto Co., Inc. Procedimiento para producir un derivado de fenilalanina que tiene esqueleto de quinazolindiona e intermedio para el mismo
WO2005046696A1 (ja) * 2003-11-14 2005-05-26 Ajinomoto Co., Inc. フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
EP3216449A1 (en) * 2003-11-14 2017-09-13 EA Pharma Co., Ltd. Oral administration preparation of phenylalanine derivatives
WO2005051925A1 (ja) * 2003-11-27 2005-06-09 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶及びその製造方法
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
EP1765400A2 (en) * 2004-06-04 2007-03-28 Genentech, Inc. Method for treating lupus
ZA200610158B (en) * 2004-06-04 2008-07-30 Genentech Inc Method for treating multiple sclerosis
DE602006012839D1 (de) 2005-05-20 2010-04-22 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
EP2402326A1 (en) 2005-06-21 2012-01-04 Ajinomoto Co., Inc. Crystals of hydrochloride salts of a Phenylalanine Derivative, Production Method Thereof and Use Thereof as alpha4 integrin Inhibitors
US20090111828A1 (en) * 2005-11-23 2009-04-30 Astrazeneca Ab L-alanine derivatives
CN103265495B (zh) * 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
UY30244A1 (es) * 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
AR060901A1 (es) 2006-05-12 2008-07-23 Jerini Ag Compuestos heterociclicos para la inhibicion de integrinas y uso de estos
EP2049490A1 (en) * 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
US7879837B2 (en) 2006-06-19 2011-02-01 Toray Industries, Inc. Therapeutic or prophylactic agent for multiple sclerosis
ES2358291T3 (es) * 2006-06-20 2011-05-09 Toray Industries, Inc. Agente terapéutico o profiláctico para la leucemia.
MX297306B (es) 2006-11-22 2012-03-22 Ajinomoto Kk Procedimiento para la produccion de derivados de fenilalanina que tienen estructuras de base de quinazolinodiona e intermediarios para la produccion.
US20090062267A1 (en) * 2007-01-29 2009-03-05 Astrazeneca Ab L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
ES2768349T3 (es) 2010-03-29 2020-06-22 Ea Pharma Co Ltd Preparación farmacéutica que comprende un derivado de fenilalanina
EP2853529A1 (en) * 2010-03-29 2015-04-01 Ajinomoto Co., Inc. Crystals of salts of phenylalanine derivatives
MX2014004319A (es) 2011-10-17 2015-05-15 Univ Muenster Wilhelms Valoracion del riesgo de pml (leucoencefalopatia multifocal progresiva) y metodos basados en la misma.
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
DK2842945T3 (en) * 2012-04-24 2017-01-30 Ea Pharma Co Ltd Sulfonamide derivative and medical use thereof
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
WO2014201172A1 (en) * 2013-06-11 2014-12-18 Receptos, Inc. Novel glp-1 receptor modulators
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
AU2014341188B2 (en) 2013-10-29 2017-05-25 Ea Pharma Co., Ltd. Sulfonamide derivative and medicinal use thereof
WO2016051828A1 (ja) * 2014-09-29 2016-04-07 味の素株式会社 潰瘍性大腸炎の治療用医薬組成物
US10307535B2 (en) 2014-12-19 2019-06-04 Medtronic Minimed, Inc. Infusion devices and related methods and systems for preemptive alerting
CA2981371A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
PT3359572T (pt) 2015-10-06 2025-01-27 H Hoffnabb La Roche Ag Método para o tratamento da esclerose múltipla
HUE053354T2 (hu) 2016-02-05 2021-06-28 Ea Pharma Co Ltd Szulfonamid-származékok és ezeket tartalmazó gyógyászati készítmények
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US11963996B2 (en) * 2018-10-24 2024-04-23 Orthotrophix, Inc. Method of treating knee pain
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
HRP20250191T1 (hr) 2018-10-30 2025-04-11 Gilead Sciences, Inc. Derivati 3-(kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diona kao inhibitori alfa4beta7 integrina za liječenje upalnih bolesti
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
KR20210098998A (ko) 2018-12-04 2021-08-11 오르토트로픽스 인코포레이티드 골관절염 치료시 사용하기 위한 제형
EP4013499A1 (en) * 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2022072156A1 (en) 2020-10-01 2022-04-07 Orthotrophix, Inc. Hard tissue therapeutics
WO2025058075A1 (ja) * 2023-09-13 2025-03-20 国立大学法人大阪大学 放射性陽電子放出核種炭素１１標識化合物、及び放射性組成物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2419928A1 (fr) * 1978-03-15 1979-10-12 Metabio Joullie Sa Nouveaux derives de la n-phenylalanine, leur preparation et leur application comme medicaments
DE4111394A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
HU914U (en) 1995-04-19 1996-10-28 Koevesi Machine tool for contour turning
ATE267817T1 (de) 1997-02-28 2004-06-15 Pfizer Prod Inc Atropisomere von 3-aryl-4(3h)-chinazolinonen und ihre verwendung als ampa-rezeptor
NZ502582A (en) 1997-07-31 2002-07-26 American Home Prod Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
WO1999006437A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals Inc. Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
ID24304A (id) * 1997-08-22 2000-07-13 Hoffmann La Roche N-alkanoylphenylalanine derivatives
EP1005446B1 (en) 1997-08-22 2004-02-25 F. Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999043642A1 (en) 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
GB2354440A (en) 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
DE60033684T2 (de) * 1999-11-18 2007-12-06 Ajinomoto Co., Inc. Phenylalaninderivate
WO2001042215A1 (en) 1999-12-06 2001-06-14 F. Hoffmann-La Roche Ag 4-pyridinyl-n-acyl-l-phenylalanines
AU783348B2 (en) 1999-12-06 2005-10-20 F. Hoffmann-La Roche Ag 4-pyrimidinyl-N-acyl-L-phenylalanines
AU2224901A (en) * 1999-12-28 2001-07-09 Ajinomoto Co., Inc. Novel phenylalanine derivatives
WO2001070670A1 (en) 2000-03-23 2001-09-27 Ajinomoto Co., Inc. Novel phenylalanine derivative
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
NZ524122A (en) 2000-08-18 2005-02-25 Ajinomoto Kk Phenylalanine derivatives useful as pharmaceutical agents
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
DE60124573T2 (de) 2000-09-29 2007-06-21 Ajinomoto Co., Inc. Neue phenylalanin-derivate
WO2003010135A1 (en) * 2001-07-26 2003-02-06 Ajinomoto Co., Inc. Novel phenylpropionic acid derivatives
WO2003053926A1 (en) 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Novel phenylalanine derivative
EP1477482B1 (en) * 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Novel phenylalanine derivative
ES2548419T3 (es) * 2003-02-20 2015-10-16 Ajinomoto Co., Inc. Procedimiento para producir un derivado de fenilalanina que tiene esqueleto de quinazolindiona e intermedio para el mismo
WO2005051925A1 (ja) * 2003-11-27 2005-06-09 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶及びその製造方法
KR101194176B1 (ko) 2003-12-22 2012-10-24 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
EP2402326A1 (en) 2005-06-21 2012-01-04 Ajinomoto Co., Inc. Crystals of hydrochloride salts of a Phenylalanine Derivative, Production Method Thereof and Use Thereof as alpha4 integrin Inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337628B1 (no) * 2003-12-22 2016-05-18 Ajinomoto Kk Fenylalaninderivater eller farmasøytiske akseptable salter derav, en farmasøytisk sammensetning, en α4 integrin antagonist og et terapeutisk middel

Also Published As

Publication number Publication date
EP1288205B1 (en) 2011-02-02
BG66085B1 (bg) 2011-03-31
DE60143984D1 (de) 2011-03-17
NZ524122A (en) 2005-02-25
CZ302653B6 (cs) 2011-08-17
US20060223836A1 (en) 2006-10-05
JP3440469B2 (ja) 2003-08-25
US20110065918A1 (en) 2011-03-17
BRPI0113331B8 (pt) 2021-05-25
AU7874001A (en) 2002-03-04
EP1288205A4 (en) 2007-05-23
US20030220268A1 (en) 2003-11-27
WO2002016329A1 (en) 2002-02-28
IL154350A0 (en) 2003-09-17
PT1288205E (pt) 2011-05-06
HUP0302997A3 (en) 2004-03-29
BG107555A (bg) 2003-09-30
CN1325480C (zh) 2007-07-11
US20120253041A1 (en) 2012-10-04
DK1288205T3 (da) 2011-05-23
US7153963B2 (en) 2006-12-26
NO325738B1 (no) 2008-07-14
YU12203A (sh) 2006-03-03
CA2420040C (en) 2009-02-03
PL223152B1 (pl) 2016-10-31
BR0113331B1 (pt) 2017-11-14
PL361383A1 (en) 2004-10-04
SK287781B6 (sk) 2011-09-05
US8426588B2 (en) 2013-04-23
CA2420040A1 (en) 2003-02-18
ATE497385T1 (de) 2011-02-15
AU2001278740B9 (en) 2006-09-28
TWI229077B (en) 2005-03-11
BR0113331A (pt) 2004-02-25
CN1469867A (zh) 2004-01-21
EP1288205A1 (en) 2003-03-05
AU2001278740B2 (en) 2006-04-06
UA74385C2 (uk) 2005-12-15
KR100675036B1 (ko) 2007-01-29
KR20030048011A (ko) 2003-06-18
HUP0302997A2 (hu) 2004-01-28
US7872125B2 (en) 2011-01-18
SI1288205T1 (sl) 2011-05-31
US8222405B2 (en) 2012-07-17
CZ2003481A3 (cs) 2003-06-18
IL154350A (en) 2010-02-17
NO20030744D0 (no) 2003-02-17
SK1912003A3 (en) 2003-07-01
HU228914B1 (hu) 2013-06-28
MXPA03001495A (es) 2003-06-06
RU2286340C2 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
DK1288205T3 (da) Nye phenylalanin-derivater
ATE355269T1 (de) Phenylalaninderivate
ATE464299T1 (de) Neues phenylalaninderivat
EP2615087A3 (en) Phenylalanine derivatives
FR18C1024I2 (fr) Derives d'heterocyclocarboxamide
ECSP066311A (es) Derivados de la piperazina y su uso como agentes terapéuticos
EA200100678A1 (ru) N-уреидоалкил-пиперидины в качестве модуляторов активности рецепторов хемокинов
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ATE547416T1 (de) Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel
ATE332903T1 (de) Kondensierte pyridoindolderivate
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
ATE253359T1 (de) Antithrombotische mittel
NO20054662D0 (no) Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
FI20020360A0 (fi) Biologisesti aktiivisen tuotteen uusi käyttö
FR2848110B1 (fr) Produit d'hygiene buccodentaire a usage humain et veterinaire a base de melatonine utilisee comme principe actif
ATE286395T1 (de) Antithrombotische mittel
TR200200017T2 (tr) Benzofuran türevleri
SE9902742D0 (sv) New pharmaceutical formultion
DE60336549D1 (de) Hepatoprotektor aktivität von 2'-p-hydroxybenzoylmussaenosidsäure
DE50310743D1 (de) Wässrige formulierungen von (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4- trifluorbutan-1-sulfonat
ITRM20000624A0 (it) Uso di derivati dell'acidocinnamico come agenti insetticidi.
HN2002000113A (es) Sales tartrato de 5, 8, 14 - triazatetraciclo [10.3.1.02,11.04,9] hexadeca - 2 (11), 3,5,7,9 - pentaeno y composiciones farmaceuticas de las mismas.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: EA PHARMA CO. LTD., JP

MM1K Lapsed by not paying the annual fees